ClinicalTrials.gg
CompletedNCT03436849Updated Oct 16, 2024

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ESN364 in Healthy Japanese Male and Pre- and Post-menopausal Female Subjects

A Phase 1 interventional study of ESN364 and Placebo in Healthy Subjects, sponsored by Astellas Pharma Inc. Completed at 1 site in Japan. Open to participants aged 20 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-16.

Sponsored by Astellas Pharma Inc · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
44
Allocation
Randomized
Ages
20 Years to 64 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate the safety and tolerability of single and multiple oral doses of ESN364 in healthy Japanese male and pre- and post-menopausal female subjects. This study will also evaluate the pharmacokinetics (PK) of ESN364 and its metabolite, and the pharmacodynamics (PD) of ESN364 after single and multiple oral doses administration in healthy Japanese male and pre- and post-menopausal female subjects.

Read the detailed description

This study consists of two parts. Part 1; Single Dose (SD) and Part 2; Single and Multiple Dose (SD and MD).

02

Conditions studied

  • Healthy Subjects

Keywords

  • ASP2693
  • Pharmacodynamics
  • Pharmacokinetics
  • ESN364
  • Safety
03

In context

Lead sponsor

Astellas Pharma Inc is the lead sponsor of 525 studies on the registry; 4 are open to participants now.

Of its 28 completed or terminated interventional studies of FDA-regulated products, 19 (68%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male subject between 20 to \< 45 years of age, or female subject between 20 to \< 65 years of age.
  • Body weight at screening: ≥ 50.0 kg and \< 80.0 kg for male, ≥ 40.0 kg and \< 70.0 kg for female.
  • (BMI) at screening: range of ≥ 17.6 kg/m2 and \< 26.4 kg/m2 [BMI = Body weight (kg) ÷ {Body height (m)2}].

Exclusion criteria

Exclusion Criteria:

  • Subjects who participated or are scheduled to participate in any clinical trials or post-marketing studies within 84 days prior to screening.
  • Subject has had previous exposure with ESN364.
  • Subject has any history of allergic conditions prior to study drug administration.
  • Subject has any history or evidence of any clinically significant cardiovascular, gastrointestinal, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal, and/or other major disease or .
  • Subject has contracted pyretic or symptomatic viral, bacterial, or fungal infection within 7 days prior to hospital admission.
  • Any deviation from the normal range of blood pressure, pulse, body temperature, or routine 12-lead at screening or on the day of hospital admission.
  • Subjects who has any significantly abnormal results of laboratory tests at screening or on the day of hospital admission.
  • Subjects who are positive for any of urinary drug abuse test or serology test at screening.
  • Subject took a drug or underwent therapy within 2 weeks prior to hospital admission.
  • Subjects used a drug or underwent therapy that affects sex hormones within 3 months prior to hospital admission.
  • Subjects who had bilateral orchiectomy.
  • Subject has used any inducer of metabolism in the 3 months prior to hospital admission.
  • Subject has a history of smoking more than 10 cigarettes per day within 3 months prior to screening test.
  • Subject consumes, on average, more than approximately 500 mg/day of caffeine
  • Subject has a history of consuming more than 30 units of alcoholic beverages per week within 6 months prior to screening or has a history of alcoholism or drug/chemical/ substance abuse within past 2 years prior to screening.
  • Subjects who conducted or is scheduled to conduct any blood donation or blood drawing.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
44 participants (actual)

Study arms

  • Experimental
    ESN364 dose-1 group in Part 1

    Healthy male subjects will receive a single dose of ESN364.

    Drug: ESN364

  • Experimental
    ESN364 dose-2 group in Part 1

    Healthy male subjects will receive a single dose of ESN364.

    Drug: ESN364

  • Placebo comparator
    Placebo group in Part 1

    Healthy male subjects will receive a single dose of Placebo.

    Drug: Placebo

  • Experimental
    Male ESN364 group in Part 2

    Healthy male subjects will receive a single dose of ESN364 followed by washout period, then receive once daily dosing of ESN364 for 10 consecutive days at the same dose level.

    Drug: ESN364

  • Experimental
    Pre-menopausal female ESN364 group in Part 2

    Healthy pre-menopausal female subjects will receive a single dose of ESN364 followed by washout period, then receive once daily dosing of ESN364 for 10 consecutive days at the same dose level.

    Drug: ESN364

  • Experimental
    Post-menopausal female ESN364 group in Part 2

    Healthy post-menopausal female subjects will receive a single dose of ESN364 followed by washout period, then receive once daily dosing of ESN364 for 10 consecutive days at the same dose level.

    Drug: ESN364

  • Placebo comparator
    Male placebo group in Part 2

    Healthy male subjects will receive a single dose of Placebo followed by washout period, then receive once daily dosing of Placebo for 10 consecutive days.

    Drug: Placebo

  • Placebo comparator
    Pre-menopausal female placebo group in Part 2

    Healthy pre-menopausal female subjects will receive a single dose of Placebo followed by washout period, then receive once daily dosing of Placebo for 10 consecutive days.

    Drug: Placebo

  • Placebo comparator
    Post-menopausal female placebo group in Part 2

    Healthy post-menopausal female subjects will receive a single dose of Placebo followed by washout period, then receive once daily dosing of Placebo for 10 consecutive days.

    Drug: Placebo

Interventions

  • DrugESN364

    ESN364 will be administered orally.

  • DrugPlacebo

    Placebo will be administered orally.

06

What researchers measure

Primary outcomes

  1. Safety assessed by incidence of adverse events (AEs) in Part 1

    AEs will be coded using Medical Dictionary for Regulatory Activities (MedDRA).

    Time frame: Up to Day 12 in Part 1

  2. Safety assessed by incidence of AEs in Part 2

    AEs will be coded using MedDRA.

    Time frame: Up to Day 24 in Part 2

  3. Safety assessed by vital signs: Body temperature in Part 1

    To assess vital signs as a criterion of safety variables.

    Time frame: Up to day 12 in Part 1

  4. Safety assessed by vital signs: Body temperature in Part 2

    To assess vital signs as a criterion of safety variables.

    Time frame: Up to Day 24 in Part 2

  5. Safety assessed by vital signs: Blood pressure in Part 1

    To assess vital signs as a criterion of safety variables.

    Time frame: Up to Day 12 in Part 1

  6. Safety assessed by vital signs: Blood pressure in Part 2

    To assess vital signs as a criterion of safety variables.

    Time frame: Up to Day 24 in Part 2

  7. Safety assessed by vital signs: Pulse rate in Part 1

    To assess vital signs as a criterion of safety variables.

    Time frame: Up to Day 12 in Part 1

  8. Safety assessed by vital signs: Pulse rate in Part 2

    To assess vital signs as a criterion of safety variables.

    Time frame: Up to Day 24 in Part 2

  9. Safety assessed by laboratory test: Hematology in Part 1

    To assess laboratory values as a criterion of safety variables. Potentially clinically significant laboratory values will be reported as AEs.

    Time frame: Up to Day 12 in Part 1

  10. Safety assessed by laboratory test: Hematology in Part 2

    To assess laboratory values as a criterion of safety variables. Potentially clinically significant laboratory values will be reported as AEs.

    Time frame: Up to Day 24 in Part 2

  11. Safety assessed by laboratory test: Biochemistry in Part 1

    To assess laboratory values as a criterion of safety variables. Potentially clinically significant laboratory values will be reported as AEs.

    Time frame: Up to Day 12 in Part 1

  12. Safety assessed by laboratory test: Biochemistry in Part 2

    To assess laboratory values as a criterion of safety variables. Potentially clinically significant laboratory values will be reported as AEs.

    Time frame: Up to Day 24 in Part 2

  13. Safety assessed by laboratory test: Urinalysis in Part 1

    To assess laboratory values as a criterion of safety variables. Potentially clinically significant laboratory values will be reported as AEs.

    Time frame: Up to Day 12 in Part 1

  14. Safety assessed by laboratory test: Urinalysis in Part 2

    To assess laboratory values as a criterion of safety variables. Potentially clinically significant laboratory values will be reported as AEs.

    Time frame: Up to Day 24 in Part 2

  15. Safety assessed by standard 12-lead electrocardiogram (ECG) in Part 1

    Subjects should keep rest for 5 minutes before evaluation. Any clinically significant adverse changes on the ECG will be reported as AEs.

    Time frame: Up to Day 12 in Part 1

  16. Safety assessed by standard ECG in Part 2

    Subjects should keep rest for 5 minutes before evaluation. Any clinically significant adverse changes on the ECG will be reported as AEs.

    Time frame: Up to Day 24 in Part 2

  17. Safety assessed by ECG parameters: Heart rate in Part 1

    To assess ECG parameters as a criterion of safety variables.

    Time frame: Up to 24 hr after dosing in Part 1

  18. Safety assessed by ECG parameters: Heart rate in Part 2

    To assess ECG parameters as a criterion of safety variables.

    Time frame: Up to 24 hr after dosing on Day 10 in multiple dose (MD) of Part 2

  19. Safety assessed by ECG parameters: QT interval in Part 1

    To assess ECG parameters as a criterion of safety variables.

    Time frame: Up to 24 hr after dosing in Part 1

  20. Safety assessed by ECG parameters: QT interval in Part 2

    To assess ECG parameters as a criterion of safety variables.

    Time frame: Up to 24 hr after dosing on Day 10 in MD of Part 2

  21. Safety assessed by ECG parameters: RR interval in Part 1

    To assess ECG parameters as a criterion of safety variables.

    Time frame: Up to 24 hr after dosing in Part 1

  22. Safety assessed by ECG parameters: RR interval in Part 2

    To assess ECG parameters as a criterion of safety variables.

    Time frame: Up to 24 hr after dosing on Day 10 in MD of Part 2

  23. Safety assessed by ECG parameters: PR interval in Part 1

    To assess ECG parameters as a criterion of safety variables.

    Time frame: Up to 24 hr after dosing in Part 1

  24. Safety assessed by ECG parameters: PR interval in Part 2

    To assess ECG parameters as a criterion of safety variables.

    Time frame: Up to 24 hr after dosing on Day 10 in MD of Part 2

  25. Safety assessed by ECG parameters: QRS interval in Part 1

    To assess ECG parameters as a criterion of safety variables.

    Time frame: Up to 24 hr after dosing in Part 1

  26. Safety assessed by ECG parameters: QRS interval in Part 2

    To assess ECG parameters as a criterion of safety variables.

    Time frame: Up to 24 hr after dosing on Day 10 in MD of Part 2

  27. Safety assessed by ECG parameters: QTc interval corrected by Fridericia method (QTcF) in Part 1

    To assess ECG parameters as a criterion of safety variables.

    Time frame: Up to 24 hr after dosing in Part 1

  28. Safety assessed by ECG parameters: QTcF in Part 2

    To assess ECG parameters as a criterion of safety variables.

    Time frame: Up to 24 hr after dosing on Day 10 in MD of Part 2

  29. Safety assessed by body weight in Part 1

    To assess body weight as a criterion of safety variables

    Time frame: Up to Day 3 in Part 1

  30. Safety assessed by body weight in Part 2

    To assess body weight as a criterion of safety variables

    Time frame: Up to Day 15 in Part 2

  31. Safety assessed by menstrual cycle in pre-menopausal females

    To assess menstrual cycle as a criterion of safety variables

    Time frame: Up to an average of two weeks after last dosing

Secondary outcomes

  1. Pharmacokinetics (PK) parameter for ESN364 and its metabolite: Area under the concentration-time curve (AUC) from the time of dosing to time 24 h (AUC24) in plasma

    To assess the PK of ESN364 and its metabolite in Part 1 and Part 2.

    Time frame: Up to 48 hr after dosing in Part 1 and after first dosing in Part 2

  2. PK parameter for ESN364 and its metabolite: AUC from the time of dosing extrapolated to time infinity (AUCinf) in plasma

    To assess the PK of ESN364 and its metabolite4 in Part 1 and Part 2.

    Time frame: Up to 48 hr after dosing in Part 1 and after first dosing in Part 2

  3. PK parameter for ESN364 and its metabolite: Percentage of AUCinf (AUCinf(%extrap)) in plasma

    To assess the PK of ESN364 and its metabolite in Part 1.

    Time frame: Up to 48 hr after dosing in Part 1

  4. PK parameter for ESN364 and its metabolite: AUC from the time of dosing to the last measurable concentration (AUClast) in plasma

    To assess the PK of ESN364 and its metabolite in Part 1.

    Time frame: Up to 48 hr after dosing in Part 1

  5. PK parameter for ESN364 and its metabolite: Maximum concentration (Cmax) in plasma

    To assess the PK of ESN364 and its metabolite in Part 1 and Part 2.

    Time frame: Up to 48 hr after dosing in Part 1, after first dosing in Part 2 and after dosing on Day 10 in MD part of Part 2

  6. PK parameter for ESN364 and its metabolite: Apparent total clearance after extra-vascular dosing (CL/F) in plasma

    To assess the PK of ESN364 and its metabolite in Part 1 and Part 2.

    Time frame: Up to 48 hr after dosing in Part 1 and after dosing on Day 10 in MD part of Part 2

  7. PK parameter for ESN364 and its metabolite: Time point prior to the time point corresponding to the first measurable (non-zero) concentration (tlag) in plasma

    To assess the PK of ESN364 and its metabolite in Part 1 and Part 2.

    Time frame: Up to 48 hr after dosing in Part 1, after first dosing in Part 2 and after dosing on Day 10 in MD part of Part 2

  8. PK parameter for ESN364 and its metabolite: Time of the maximum concentration: (tmax) in plasma

    To assess the PK of ESN364 and its metabolite in Part 1 and Part 2.

    Time frame: Up to 48 hr after dosing in Part 1, after first dosing in Part 2 and after dosing on Day 10 in MD part of Part 2

  9. PK parameter for ESN364 and its metabolite: Terminal elimination half-life (t1/2) in plasma

    To assess the PK of ESN364 and its metabolite in Part 1 and Part 2.

    Time frame: Up to 48 hr after dosing in Part 1 and after dosing on Day 10 in MD part of Part 2

  10. PK parameter for ESN364 and its metabolite: volume of distribution during the terminal elimination phase after extra-vascular dosing (Vz/F) in plasma

    To assess the PK of ESN364 and its metabolite in Part 1 and Part 2.

    Time frame: Up to 48 hr after dosing in Part 1 and after dosing on Day 10 in MD part of Part 2

  11. PK parameter for ESN364 metabolite: Metabolite to parent ratio (MPR) in plasma

    To assess the PK of ESN364 metabolite in Part 1 and Part 2.

    Time frame: Up to 48 hr after dosing in Part 1, after first dosing in Part 2 and after dosing on Day 10 in MD part of Part 2

  12. PK parameter for ESN364 and its metabolite: AUC from the time of dosing to the start of the next dosing interval (AUCtau) in plasma

    To assess the PK of ESN364 and its metabolite in Part 2.

    Time frame: Up to 48 hr after dosing on Day 10 in MD part of Part 2

  13. PK parameter for ESN364 and its metabolite: Peak-trough ratio (PTR) in plasma

    To assess the PK of ESN364 and its metabolite in Part 2.

    Time frame: Up to 48 hr after dosing on Day 10 in MD part of Part 2

  14. PK parameter for ESN364 and its metabolite: Accumulation ratio calculated using AUC (Rac(AUC)) in plasma

    To assess the PK of ESN364 and its metabolite in Part 2.

    Time frame: Up to 48 hr after dosing on Day 10 in MD part of Part 2

  15. PK parameter for ESN364 and its metabolite: Concentration immediately prior to dosing at multiple dosing (Ctrough) in plasma

    To assess the PK of ESN364 and its metabolite in Part 2.

    Time frame: Before dosing on Day 2, 3, 5, 7 and 10 in MD part of Part 2

  16. Pharmacodynamic (PD) endpoint for ESN364: Luteinizing hormone (LH) level in plasma

    To assess the PD of ESN364 in Part 1 and Part 2.

    Time frame: Up to 48 hr after dosing in Part 1, after first dosing in Part 2 and after dosing on Day 10 in MD part of Part 2

  17. PD endpoint for ESN364: AUC12 for LH level

    To assess the PD of ESN364 in Part 1 and Part 2.

    Time frame: Up to 48 hr after dosing in Part 1 and after first dosing in Part 2.

  18. PD endpoint for ESN364: AUC24 for LH level

    To assess the PD of ESN364 in Part 1 and Part 2.

    Time frame: Up to 48 hr after dosing in Part 1 and after first dosing in Part 2.

  19. PD endpoint for ESN364: AUC48 for LH level

    To assess the PD of ESN364 in Part 1 and Part 2.

    Time frame: Up to 48 hr after dosing in Part 1 and after first dosing in Part 2.

  20. PD endpoint for ESN364: Cmin for LH level

    To assess the PD of ESN364 in Part 1 and Part 2.

    Time frame: Up to 48 hr after dosing in Part 1, after first dosing in Part 2 and after dosing on Day 10 in MD part of Part 2

  21. PD endpoint for ESN364: tmin for LH level

    To assess the PD of ESN364 in Part 1 and Part 2.

    Time frame: Up to 48 hr after dosing in Part 1, after first dosing in Part 2 and after dosing on Day 10 in MD part of Part 2

  22. PD endpoint for ESN364: AUC from the Time of Dosing to the Start of the Next Dosing Interval (AUCtau) for LH level

    To assess the PD of ESN364 in Part 2.

    Time frame: Before dosing on Day 10 in MD part of Part 2

  23. PD endpoint for ESN364: Cpredose for LH level

    To assess the PD of ESN364 in Part 1 and Part 2.

    Time frame: Before dosing in Part 1 and before dosing on Day 2, 3, 5, 7 and 10 in MD part of Part 2

  24. PD endpoint for ESN364: Follicle stimulating hormone (FSH) level in plasma

    To assess the PD of ESN364 in Part 1 and Part 2.

    Time frame: Up to 48 hr after dosing in Part 1, after first dosing in Part 2 and after dosing on Day 10 in MD part of Part 2

  25. PD endpoint for ESN364: AUC12 for FSH level

    To assess the PD of ESN364 in Part 1 and Part 2.

    Time frame: Up to 48 hr after dosing in Part 1 and after first dosing in Part 2.

  26. PD endpoint for ESN364: AUC24 for FSH level

    To assess the PD of ESN364 in Part 1 and Part 2.

    Time frame: Up to 48 hr after dosing in Part 1 and after first dosing in Part 2.

  27. PD endpoint for ESN364: AUC48 for FSH level

    To assess the PD of ESN364 in Part 1 and Part 2.

    Time frame: Up to 48 hr after dosing in Part 1 and after first dosing in Part 2.

  28. PD endpoint for ESN364: Cmin for FSH level

    To assess the PD of ESN364 in Part 1 and Part 2.

    Time frame: Up to 48 hr after dosing in Part 1, after first dosing in Part 2 and after dosing on Day 10 in MD part of Part 2

  29. PD endpoint for ESN364: tmin for FSH level

    To assess the PD of ESN364 in Part 1 and Part 2.

    Time frame: Up to 48 hr after dosing in Part 1, after first dosing in Part 2 and after dosing on Day 10 in MD part of Part 2

  30. PD endpoint for ESN364: AUCtau for FSH level

    To assess the PD of ESN364 in Part 2.

    Time frame: Before dosing on Day 10 in MD part of Part 2

  31. PD endpoint for ESN364: Cpredose for FSH level

    To assess the PD of ESN364 in Part 1 and Part 2.

    Time frame: Before dosing in Part 1 and before dosing on Day 2, 3, 5, 7 and 10 in MD part of Part 2

  32. PD endpoint for ESN364: Sex hormone binding globulin (SHBG) level in plasma

    To assess the PD of ESN364 in Part 1 and Part 2.

    Time frame: Up to 48 hr after dosing in Part 1, after first dosing in Part 2 and after dosing on Day 10 in MD part of Part 2

  33. PD endpoint for ESN364: AUC12 for SHBG level

    To assess the PD of ESN364 in Part 1 and Part 2.

    Time frame: Up to 48 hr after dosing in Part 1 and after first dosing in Part 2.

  34. PD endpoint for ESN364: AUC24 for SHBG level

    To assess the PD of ESN364 in Part 1 and Part 2.

    Time frame: Up to 48 hr after dosing in Part 1 and after first dosing in Part 2.

  35. PD endpoint for ESN364: AUC48 for SHBG level

    To assess the PD of ESN364 in Part 1 and Part 2.

    Time frame: Up to 48 hr after dosing in Part 1 and after first dosing in Part 2.

  36. PD endpoint for ESN364: Cmin for SHBG level

    To assess the PD of ESN364 in Part 1 and Part 2.

    Time frame: Up to 48 hr after dosing in Part 1, after first dosing in Part 2 and after dosing on Day 10 in MD part of Part 2

  37. PD endpoint for ESN364: tmin for SHBG level

    To assess the PD of ESN364 in Part 1 and Part 2.

    Time frame: Up to 48 hr after dosing in Part 1, after first dosing in Part 2 and after dosing on Day 10 in MD part of Part 2

  38. PD endpoint for ESN364: AUCtau for SHBG level

    To assess the PD of ESN364 in Part 2.

    Time frame: Before dosing on Day 10 in MD part of Part 2

  39. PD endpoint for ESN364: Cpredose for SHBG level

    To assess the PD of ESN364 in Part 1 and Part 2.

    Time frame: Before dosing in Part 1 and before dosing on Day 2, 3, 5, 7 and 10 in MD part of Part 2

  40. PD endpoint for ESN364: Total testosterone (TT) level in plasma

    To assess the PD of ESN364 in Part 1 and Part 2.

    Time frame: Up to 48 hr after dosing in Part 1, after first dosing in Part 2 and after dosing on Day 10 in MD part of Part 2

  41. PD endpoint for ESN364: AUC24 for TT level

    To assess the PD of ESN364 in Part 1 and Part 2.

    Time frame: Up to 48 hr after dosing in Part 1 and after first dosing in Part 2.

  42. PD endpoint for ESN364: AUC12 for TT level

    To assess the PD of ESN364 in Part 1 and Part 2.

    Time frame: Up to 48 hr after dosing in Part 1 and after first dosing in Part 2.

  43. PD endpoint for ESN364: AUC48 for TT level

    To assess the PD of ESN364 in Part 1 and Part 2.

    Time frame: Up to 48 hr after dosing in Part 1 and after first dosing in Part 2.

  44. PD endpoint for ESN364: Cmin for TT level

    To assess the PD of ESN364 in Part 1 and Part 2.

    Time frame: Up to 48 hr after dosing in Part 1, after first dosing in Part 2 and after dosing on Day 10 in MD part of Part 2

  45. PD endpoint for ESN364: tmin for TT level

    To assess the PD of ESN364 in Part 1 and Part 2.

    Time frame: Up to 48 hr after dosing in Part 1, after first dosing in Part 2 and after dosing on Day 10 in MD part of Part 2

  46. PD endpoint for ESN364: AUCtau for TT level

    To assess the PD of ESN364 in Part 2.

    Time frame: Before dosing on Day 10 in MD part of Part 2

  47. PD endpoint for ESN364: Cpredose for TT level

    To assess the PD of ESN364 in Part 1 and Part 2.

    Time frame: Before dosing in Part 1 and before dosing on Day 2, 3, 5, 7 and 10 in MD part of Part 2

  48. PD endpoint for ESN364: Free testosterone (FT) level in plasma

    To assess the PD of ESN364 in Part 1 and Part 2.

    Time frame: Up to 48 hr after dosing in Part 1, after first dosing in Part 2 and after dosing on Day 10 in MD part of Part 2

  49. PD endpoint for ESN364: AUC12 for FT level

    To assess the PD of ESN364 in Part 1 and Part 2.

    Time frame: Up to 48 hr after dosing in Part 1 and after first dosing in Part 2.

  50. PD endpoint for ESN364: AUC24 for FT level

    To assess the PD of ESN364 in Part 1 and Part 2.

    Time frame: Up to 48 hr after dosing in Part 1 and after first dosing in Part 2.

  51. PD endpoint for ESN364: AUC48 for FT level

    To assess the PD of ESN364 in Part 1 and Part 2.

    Time frame: Up to 48 hr after dosing in Part 1 and after first dosing in Part 2.

  52. PD endpoint for ESN364: Cmin for FT level

    To assess the PD of ESN364 in Part 1 and Part 2.

    Time frame: Up to 48 hr after dosing in Part 1, after first dosing in Part 2 and after dosing on Day 10 in MD part of Part 2

  53. PD endpoint for ESN364: tmin for FT level

    To assess the PD of ESN364 in Part 1 and Part 2.

    Time frame: Up to 48 hr after dosing in Part 1, after first dosing in Part 2 and after dosing on Day 10 in MD part of Part 2

  54. PD endpoint for ESN364: AUCtau for FT level

    To assess the PD of ESN364 in Part 2.

    Time frame: Before dosing on Day 10 in MD part of Part 2

  55. PD endpoint for ESN364: Cpredose for FT level

    To assess the PD of ESN364 in Part 1 and Part 2.

    Time frame: Before dosing in Part 1 and before dosing on Day 2, 3, 5, 7 and 10 in MD part of Part 2

  56. PD endpoint for ESN364: Estradiol (E) level in plasma

    To assess the PD of ESN364 in female subjects in Part 2.

    Time frame: Up to 48 hr after first dosing in Part 2 and after dosing on Day 10 in MD part of Part 2

  57. PD endpoint for ESN364: AUC12 for E level

    To assess the PD of ESN364 in female subjects in Part 2.

    Time frame: Up to 48 hr after first dosing in Part 2.

  58. PD endpoint for ESN364: AUC24 for E level

    To assess the PD of ESN364 in female subjects in Part 2.

    Time frame: Up to 48 hr after first dosing in Part 2.

  59. PD endpoint for ESN364: AUC48 for E level

    To assess the PD of ESN364 in female subjects in Part 2.

    Time frame: Up to 48 hr after first dosing in Part 2.

  60. PD endpoint for ESN364: Cmin for E level

    To assess the PD of ESN364 in female subjects in Part 2.

    Time frame: Up to 48 hr after first dosing in Part 2 and after dosing on Day 10 in MD part of Part 2

  61. PD endpoint for ESN364: tmin for E level

    To assess the PD of ESN364 in female subjects in Part 2.

    Time frame: Up to 48 hr after first dosing in Part 2 and after dosing on Day 10 in MD part of Part 2

  62. PD endpoint for ESN364: AUCtau for E level

    To assess the PD of ESN364 in female subjects in Part 2.

    Time frame: Before dosing on Day 10 in MD part of Part 2

  63. PD endpoint for ESN364: Cpredose for E level

    To assess the PD of ESN364 in female subjects in Part 2.

    Time frame: Before dosing on Day 2, 3, 5, 7 and 10 in MD part of Part 2

  64. PD endpoint for ESN364: Progesterone (P) level in plasma

    To assess the PD of ESN364 in female subjects in Part 2.

    Time frame: Up to 48 hr after first dosing in Part 2 and after dosing on Day 10 in MD part of Part 2

  65. PD endpoint for ESN364: AUC12 for P level

    To assess the PD of ESN364 in female subjects in Part 2.

    Time frame: Up to 48 hr after first dosing in Part 2.

  66. PD endpoint for ESN364: AUC24 for P level

    To assess the PD of ESN364 in female subjects in Part 2.

    Time frame: Up to 48 hr after first dosing in Part 2.

  67. PD endpoint for ESN364: AUC48 for P level

    To assess the PD of ESN364 in female subjects in Part 2.

    Time frame: Up to 48 hr after first dosing in Part 2.

  68. PD endpoint for ESN364: Cmin for P level

    To assess the PD of ESN364 in female subjects in Part 2.

    Time frame: Up to 48 hr after first dosing in Part 2 and after dosing on Day 10 in MD part of Part 2

  69. PD endpoint for ESN364: tmin for P level

    To assess the PD of ESN364 in female subjects in Part 2.

    Time frame: Up to 48 hr after first dosing in Part 2 and after dosing on Day 10 in MD part of Part 2

  70. PD endpoint for ESN364: AUCtau for P level

    To assess the PD of ESN364 in female subjects in Part 2.

    Time frame: Before dosing on Day 10 in MD part of Part 2

  71. PD endpoint for ESN364: Cpredose for P level

    To assess the PD of ESN364 in female subjects in Part 2.

    Time frame: Before dosing on Day 2, 3, 5, 7 and 10 in MD part of Part 2

07

Study locations

1 site
  • Site JP00001
    Fukuoka, Japan
08

References and documents

Individual participant data

Plan to share: No — Access to anonymized individual participant level data will not be provided for this trial. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2018 to primary completion in May 2018, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 30, 2018
First posted
Feb 19, 2018
StartActual
Feb 22, 2018
Primary completionActual
May 23, 2018
CompletionActual
May 23, 2018
Last update
Oct 16, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03436849
Responsible party
Sponsor
First posted
Feb 19, 2018
Start date
Feb 22, 2018
Primary completion
May 23, 2018
Completion
May 23, 2018
Last update
Oct 16, 2024

Study contacts

Medical Director
study director · Astellas Pharma Inc

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fezolinetant

Start the discussion